The importance of preserving choice in inhalation therapy

the CFC transition and beyond

David Brendan Price, E. Valovirta, J. Fischer

Research output: Contribution to journalEditorial

Abstract

Inhaled therapy is a mainstay of asthma and chronic obstructive pulmonary disease (COPD) treatment. Metered dose inhalers (MDIs) using chlorofluorocarbon (CFC) propellants are currently the most widely used type of inhaler in the world. In 1987, the Montreal Protocol precipitated the change from CFC technologies to ozone-friendly alternatives, a process which is curently under way and requires the transition of millions of patients to new drug delivery systems, primarily MDIs using hydrofluorocarbons (HFCs). However, HFCs have been identified as greenhouse gases and are now being evaluated under a separate global climate change treaty (the Kyoto Protocol).
Against this unique background, this paper looks at the role of inhalation therapy in the treatment of lung disease and examines the factors which influence both primary care prescribers and patients in their choice of the most appropriate drug/device combination. It is important that switching therapy for non-therapeutic reasons does not constrain this choice.
Very little information on the effects of the CFC transition on patients and physicians is yet available. Given how important it is for effective treatment that a choice of inhaler device is maintained, the experience of the current transition should be more fully evaluated as a context for futher environmental policy measures. Any measures that could affect patient use of HFC-MDIs should be carefully considered by all stakeholders, especially if these are imposed while the transition of patients from CFC-MDIs is still in progress.

Original languageEnglish
Pages (from-to)45-61
Number of pages16
JournalJournal of Drug Assessment
Volume7
Issue number2
Publication statusPublished - 2004

Fingerprint

Chlorofluorocarbons
Respiratory Therapy
Metered Dose Inhalers
Patient Transfer
Nebulizers and Vaporizers
Environmental Policy
Therapeutics
International Cooperation
Equipment and Supplies
Climate Change
Ozone
Drug Combinations
Drug Delivery Systems
Chronic Obstructive Pulmonary Disease
Lung Diseases
Primary Health Care
Asthma
Gases
Technology
Physicians

Cite this

The importance of preserving choice in inhalation therapy : the CFC transition and beyond . / Price, David Brendan; Valovirta, E.; Fischer, J.

In: Journal of Drug Assessment, Vol. 7, No. 2, 2004, p. 45-61.

Research output: Contribution to journalEditorial

@article{e83100e668ff4799af228d8db3e30173,
title = "The importance of preserving choice in inhalation therapy: the CFC transition and beyond",
abstract = "Inhaled therapy is a mainstay of asthma and chronic obstructive pulmonary disease (COPD) treatment. Metered dose inhalers (MDIs) using chlorofluorocarbon (CFC) propellants are currently the most widely used type of inhaler in the world. In 1987, the Montreal Protocol precipitated the change from CFC technologies to ozone-friendly alternatives, a process which is curently under way and requires the transition of millions of patients to new drug delivery systems, primarily MDIs using hydrofluorocarbons (HFCs). However, HFCs have been identified as greenhouse gases and are now being evaluated under a separate global climate change treaty (the Kyoto Protocol). Against this unique background, this paper looks at the role of inhalation therapy in the treatment of lung disease and examines the factors which influence both primary care prescribers and patients in their choice of the most appropriate drug/device combination. It is important that switching therapy for non-therapeutic reasons does not constrain this choice. Very little information on the effects of the CFC transition on patients and physicians is yet available. Given how important it is for effective treatment that a choice of inhaler device is maintained, the experience of the current transition should be more fully evaluated as a context for futher environmental policy measures. Any measures that could affect patient use of HFC-MDIs should be carefully considered by all stakeholders, especially if these are imposed while the transition of patients from CFC-MDIs is still in progress.",
author = "Price, {David Brendan} and E. Valovirta and J. Fischer",
year = "2004",
language = "English",
volume = "7",
pages = "45--61",
journal = "Journal of Drug Assessment",
issn = "1369-9474",
number = "2",

}

TY - JOUR

T1 - The importance of preserving choice in inhalation therapy

T2 - the CFC transition and beyond

AU - Price, David Brendan

AU - Valovirta, E.

AU - Fischer, J.

PY - 2004

Y1 - 2004

N2 - Inhaled therapy is a mainstay of asthma and chronic obstructive pulmonary disease (COPD) treatment. Metered dose inhalers (MDIs) using chlorofluorocarbon (CFC) propellants are currently the most widely used type of inhaler in the world. In 1987, the Montreal Protocol precipitated the change from CFC technologies to ozone-friendly alternatives, a process which is curently under way and requires the transition of millions of patients to new drug delivery systems, primarily MDIs using hydrofluorocarbons (HFCs). However, HFCs have been identified as greenhouse gases and are now being evaluated under a separate global climate change treaty (the Kyoto Protocol). Against this unique background, this paper looks at the role of inhalation therapy in the treatment of lung disease and examines the factors which influence both primary care prescribers and patients in their choice of the most appropriate drug/device combination. It is important that switching therapy for non-therapeutic reasons does not constrain this choice. Very little information on the effects of the CFC transition on patients and physicians is yet available. Given how important it is for effective treatment that a choice of inhaler device is maintained, the experience of the current transition should be more fully evaluated as a context for futher environmental policy measures. Any measures that could affect patient use of HFC-MDIs should be carefully considered by all stakeholders, especially if these are imposed while the transition of patients from CFC-MDIs is still in progress.

AB - Inhaled therapy is a mainstay of asthma and chronic obstructive pulmonary disease (COPD) treatment. Metered dose inhalers (MDIs) using chlorofluorocarbon (CFC) propellants are currently the most widely used type of inhaler in the world. In 1987, the Montreal Protocol precipitated the change from CFC technologies to ozone-friendly alternatives, a process which is curently under way and requires the transition of millions of patients to new drug delivery systems, primarily MDIs using hydrofluorocarbons (HFCs). However, HFCs have been identified as greenhouse gases and are now being evaluated under a separate global climate change treaty (the Kyoto Protocol). Against this unique background, this paper looks at the role of inhalation therapy in the treatment of lung disease and examines the factors which influence both primary care prescribers and patients in their choice of the most appropriate drug/device combination. It is important that switching therapy for non-therapeutic reasons does not constrain this choice. Very little information on the effects of the CFC transition on patients and physicians is yet available. Given how important it is for effective treatment that a choice of inhaler device is maintained, the experience of the current transition should be more fully evaluated as a context for futher environmental policy measures. Any measures that could affect patient use of HFC-MDIs should be carefully considered by all stakeholders, especially if these are imposed while the transition of patients from CFC-MDIs is still in progress.

M3 - Editorial

VL - 7

SP - 45

EP - 61

JO - Journal of Drug Assessment

JF - Journal of Drug Assessment

SN - 1369-9474

IS - 2

ER -